Maze Therapeutics (NASDAQ:MAZE) Trading Down 5.5% - Time to Sell?

Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) shares dropped 5.5% during mid-day trading on Thursday . The company traded as low as $12.87 and last traded at $13.11. Approximately 12,683 shares changed hands during mid-day trading, a decline of 95% from the average daily volume of 237,319 shares. The stock had previously closed at $13.87.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the stock. TD Cowen upgraded shares of Maze Therapeutics to a "strong-buy" rating in a research report on Tuesday, February 25th. JPMorgan Chase & Co. assumed coverage on Maze Therapeutics in a report on Tuesday, February 25th. They issued an "overweight" rating and a $30.00 target price on the stock. Guggenheim reissued a "buy" rating and set a $19.00 price target on shares of Maze Therapeutics in a report on Wednesday, April 2nd. Leerink Partnrs upgraded Maze Therapeutics to a "strong-buy" rating in a research report on Tuesday, February 25th. Finally, Leerink Partners started coverage on Maze Therapeutics in a research report on Tuesday, February 25th. They set an "outperform" rating and a $28.00 price objective on the stock. Three investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, Maze Therapeutics currently has a consensus rating of "Buy" and an average target price of $25.67.

Maze Therapeutics Stock Down 3.1%

The stock has a 50 day simple moving average of $9.73.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last issued its earnings results on Wednesday, May 14th. The company reported ($1.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.76) by ($0.39).

Hedge Funds Weigh In On Maze Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. TRV GP IV LLC bought a new stake in Maze Therapeutics in the 1st quarter valued at $66,874,000. Frazier Life Sciences Management L.P. purchased a new position in shares of Maze Therapeutics during the first quarter valued at about $45,460,000. ARCH Venture Management LLC bought a new stake in shares of Maze Therapeutics in the first quarter worth about $45,362,000. Matrix Capital Management Company LP purchased a new stake in shares of Maze Therapeutics in the first quarter worth about $27,373,000. Finally, Alphabet Inc. bought a new position in Maze Therapeutics during the first quarter valued at approximately $26,561,000.

Maze Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.